GO
Loading...

Pfizer Inc

More

  • Giving the Grade to Five Popular Stocks Friday, 17 Oct 2008 | 2:39 PM ET

    Some stocks are more popular than others. But that doesn't mean they're always the best shares to hold. Michael Farr, president of Farr, Miller and Washington, gave his assessment of five of the most widely held companies.

  • Lilly In The "Pink"--But Then Again Not Friday, 17 Oct 2008 | 10:57 AM ET
    Effient Ad

    I don't think Eli Lilly will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration.

  • The Last Word--For Now--On Dendreon Wednesday, 8 Oct 2008 | 10:55 AM ET

    Since there should really be no compelling reason to blog or report on Dendreon and Provenge for quite awhile, here's one last hurrah.

  • Where Are The Buying Opportunities? Tuesday, 7 Oct 2008 | 6:59 PM ET

    Which stocks have been unfairly punished over the last three trading days?

  • Fear Factor Vs. Opportunity Knocking Tuesday, 7 Oct 2008 | 4:01 PM ET
    graphic_fast_money.jpg

    Wall Street struggled with another day of selling as panic seemed to accelerate into the final minutes of trading.

  • Could The Credit Crisis Help Pfizer? Monday, 6 Oct 2008 | 3:46 PM ET
    pfizer_hq.jpg

    Pretty much all of biopharma is caught in the downdraft of the markets today with the notable exception of Dendreon (data) and ImClone Systems (a deal).

  • Dendreon, ImClone & Pfizer: Your Emails Friday, 3 Oct 2008 | 10:37 AM ET

    As all eyes remain on Capitol Hill, things remain relatively quiet on the biopharma front. So, it's a good time to go through the Pharma's Market mailbag. The overwhelming majority of emails recently have been about...yeah, you guessed it...Dendreon.

  • Mad Mail: What Happened to China? Thursday, 2 Oct 2008 | 10:17 PM ET

    Plus, should I own Pfizer?

  • Stocks Fall On Bailout Uncertainty Wednesday, 1 Oct 2008 | 5:41 PM ET
    graphic_word_ofthe_street.jpg

    The Dow closed lower on Wednesday as nervous investors found it difficult to muster enthusiasm ahead of the Senate’s vote on a revamped $700 billion rescue plan.

  • The Waiting Game Continues For Lilly & ImClone Monday, 29 Sep 2008 | 10:42 AM ET
    lilly_hq.jpg

    Eli Lilly has been running direct-to-doctor ads over the past few months telling physicians that Effient, the company's new bloodthinner, is "Coming Soon". Well, it may have jumped the gun.

  • Lilly

    Today is the day the FDA is expected to make a decision on the drug. The agency could approve it outright, approve it with conditions/limitations, delay making a decision--again--and order more tests, or reject the pill.

  • S&P Slammed Monday, 22 Sep 2008 | 5:56 PM ET
    graphic_word_ofthe_street.jpg

    The Dow tumbled on Monday as investors worried a $700 billion bailout for the financial sector may not resuscitate a slumping economy...

  • Lightning Round OT: Pfizer, Vale and More Friday, 19 Sep 2008 | 6:51 PM ET

    The Lightning Round is extended in this CNBC.com exclusive feature.

  • merck_manual.jpg

    As the press release that came with the book says, "Compact enough to carry in a lab coat pocket, the paperback helps health care practitioners, particularly those who are newcomers to clinical diagnosis, understand and evaluate a wide range of symptoms."

  • Pfizer Is A Driver: "Complaining" Investor Read On! Thursday, 18 Sep 2008 | 4:40 PM ET
    pfizer_hq.jpg

    The stock posted its biggest percentage gain in nearly three years and its biggest dollar gain in more than two years, according to CNBC stock-stat maven Robert Hum.

  • Dow Plunges 500 points Monday, 15 Sep 2008 | 4:55 PM ET
    080915 Indices.jpg

    The Dow and S&P 500 fell over 4.5% today, while the Nasdaq composite dropped 3.6%, as concerns over the health of the financial sector intensified following the decision of Lehman Brothers to file for Chapter 11.

  • Pfizer: A Delay And A Deal? Tuesday, 9 Sep 2008 | 12:06 PM ET

    At the risk of getting more emails from conspiracy-theorist readers who think I report too much negative news about Pfizer, here comes another setback for the world's biggest drug company.

  • Cramer makes the call on viewers' favorite stocks.

  • Pharma Stocks

    John Sullivan, the Director of Research at Lerrink Swann, which specializes in healthcare stocks, says there is a potential trading opportunity in the sector related to F & F.

  • Celgene's Success Story Thursday, 4 Sep 2008 | 3:37 PM ET

    One of the biggest biotech success stories is among the companies featured in the afternoon sessions here at the BioCentury/Thomson Reuters investment conference.